Cumberland Pharmaceuticals Inc. Increase Decrease In Operating Lease Liability
Cumberland Pharmaceuticals Inc. (CPIX) reported Increase Decrease In Operating Lease Liability of -$452.20 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$226.85K.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$225.35K.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$173.98K, a 107.16% decline year-over-year.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$221.68K.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2025 was -$836.10K, a 146.86% decline from fiscal 2024.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2024 was $1.78M, a 52.09% decline from fiscal 2023.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2023 was $3.72M.
- Cumberland Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2022 was $0.00.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$226.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$452.20K 10-Q · filed 2026-08-07 | -$626.18K derived: sum of 3 quarters · filed 2026-08-07 | -$847.86K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | -$225.35K 10-Q · filed 2026-05-08 | -$399.33K derived: sum of 2 quarters · filed 2026-05-08 | -$621.01K derived: sum of 3 quarters · filed 2026-05-08 | -$841.96K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | -$173.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$395.66K derived: sum of 2 quarters · filed 2026-03-09 | -$616.61K derived: sum of 3 quarters · filed 2026-08-07 | -$836.10K 10-K · filed 2026-03-09 | |
| 2025-09-30 | -$221.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$442.62K derived: sum of 2 quarters · filed 2026-08-07 | -$662.12K 10-Q · filed 2025-11-07 | $1.77M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | -$220.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$440.44K 10-Q · filed 2026-08-07 | $1.99M derived: sum of 3 quarters · filed 2026-08-07 | $1.77M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | -$219.49K 10-Q · filed 2026-05-08 | $2.21M derived: sum of 2 quarters · filed 2026-05-08 | $1.99M derived: sum of 3 quarters · filed 2026-05-08 | $1.78M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.21M derived: sum of 2 quarters · filed 2026-03-09 | $2.00M derived: sum of 3 quarters · filed 2026-03-09 | $1.78M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$215.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$431.18K derived: sum of 2 quarters · filed 2025-11-07 | -$645.01K 10-Q · filed 2025-11-07 | $5.28M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | -$215.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$429.06K 10-Q · filed 2025-08-08 | $5.50M derived: sum of 3 quarters · filed 2025-08-08 | $4.34M derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | -$213.82K 10-Q · filed 2025-05-09 | $5.71M derived: sum of 2 quarters · filed 2025-05-09 | $4.55M derived: sum of 3 quarters · filed 2025-05-09 | $3.38M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $4.77M derived: sum of 2 quarters · filed 2025-03-07 | $3.60M derived: sum of 3 quarters · filed 2025-03-07 | $3.72M 10-K · filed 2025-03-07 | -$1.41M 10-K · filed 2024-03-13 |
| 2023-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$2.33M derived: sum of 2 quarters · filed 2024-11-08 | -$2.20M 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | -$1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$1.04M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $127.14K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |